carbamates has been researched along with byl719 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deuker, MM; Marsh Durban, V; McMahon, M; Phillips, WA | 1 |
| Avsar, E; Bendell, JC; Chatterjee, A; Delord, JP; Demuth, T; Elez, E; Eskens, FALM; Faris, JE; Jaeger, S; Lenz, HJ; Lolkema, MP; Maharry, K; Schellens, JHM; Schuler, M; Sharma, S; Spreafico, A; Tabernero, J; Tan, E; van Geel, RMJM; Wainberg, ZA; Yaeger, R; Yamada, Y; Yoshino, T | 1 |
| Bernards, R; Boelens, MC; Huijberts, SCFA; Opdam, FL | 1 |
1 trial(s) available for carbamates and byl719
| Article | Year |
|---|---|
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Thiazoles | 2017 |
3 other study(ies) available for carbamates and byl719
| Article | Year |
|---|---|
PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.
Topics: Animals; Carbamates; Cell Line, Tumor; Cell Proliferation; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Melanoma; Melanoma, Experimental; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Random Allocation; Sulfonamides; Thiazoles | 2015 |
Drug combo beneficial in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Sulfonamides; Thiazoles | 2015 |
Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carbamates; Cetuximab; Cohort Studies; Colorectal Neoplasms; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Retrospective Studies; Sulfonamides; Thiazoles | 2021 |